To investigate whether Mcl-1 silencing can overcome AdV-TRAIL resistance, we initially examined four melanoma cell lines (MeWo, Mel-2a, SK-Mel-19, Mel-HO) for their sensitivity to TRAIL/AdV-TRAIL. This evidence concerns the gene TNFSF10 and melanoma.